Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pentraxin Therapeutics Ltd.

Latest From Pentraxin Therapeutics Ltd.

GSK Pays $31.5 Million Upfront, Plus Milestones To Access Angiochem’s Rare Disease Technologies

GlaxoSmithKline takes aim at neurological symptoms of lysosomal storage diseases, increasing likely future competitive pressure on Sanofi's and Shire's rare disease products.

BioPharmaceutical Deals

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now

Sanofi-Aventis' much publicized pursuit - first hostile, then friendly - of Genzyme dominated biopharma news flow for more than half a year, with well timed information leaks and dramatic "he said, he said" commentary from the firms' CEOs. Such back and forth ensured continued high profile coverage until the companies officially affianced. But beyond the drama, the $20.1 billion deal, among the largest since the 2009 mega-mergers between Pfizer and Wyeth and Merck & Co. and Schering-Plough Corp., is worth discussion because it provides insight into what now drives big pharma dealmaking in the post-blockbuster era - and how companies want to pay for it.

BioPharmaceutical Legal Issues

Back To School: Big Pharmas Test New Models For Tapping Academia

Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.

BioPharmaceutical Business Strategies

Executive Briefing - Biopartnering 2.0

The biopharmaceutical industry's perennial search for innovation continues to drive diverse alliance activity between commercial partners of all stripes. More recently, the macroeconomic climate has been impacting on dealmaker behaviour, with the emergence of risk aversion, creative thinking and more emphasis on value in partners' decision making. Many firms are rethinking their relationships with leading universities as part of broader strategies to boost innovation. Expect biopartnering models to reach a new level, says Pete Chan.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies